Clinical trial · no report yet · Phase 2/Phase 3
NCT05987241
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
- NCT05987241 ↗
- Recruiting
- National Cancer Institute (NCI)
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
- Phase
- Phase 2/Phase 3
- Status
- Recruiting
- Conditions
- Muscle Invasive Bladder Urothelial Carcinoma; Muscle Invasive Renal Pelvis Urothelial Carcinoma; Muscle Invasive Ureter Urothelial Carcinoma; Muscle Invasive Urethral Urothelial Carcinoma; Stage II Bladder Urothelial Carcinoma AJCC v6 and v7; Stage III Bladder Urothelial Carcinoma AJCC v6 and v7; Stage IV Bladder Urothelial Carcinoma AJCC v7
- Interventions
- Biospecimen Collection; cfDNA or ctDNA Measurement; Computed Tomography; Cystoscopy; Magnetic Resonance Imaging; Nivolumab; Questionnaire Administration; Relatlimab
- Arms
- Cohort A, Arm I (nivolumab) · Active comparator
- Cohort A, Arm II (nivolumab, relatlimab) · Experimental
- Cohort B, Arm III (nivolumab) · Active comparator
- Cohort B, Arm IV (ctDNA surveillance, nivolumab) · Experimental
- Enrollment
- 992 (estimated)
- Primary outcomes
- Proportion of patients who are circulating tumor DNA negative (ctDNA[-]) (Cohort A Phase II)
- Overall survival (OS) (Cohort A Phase III)
- Disease-Free Survival (DFS) (Cohort B)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Feb 2, 2024
- Primary completion
- Sep 2, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT05987241 · updated Oct 9, 2026